



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: June 24, 2022

Administrative Circular: 2022:24

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 1 - Immunization Schedules, Part 4 - Biological Products, Appendix B –
Administration of Biological Products & Supporting Documents**

Part 1- Immunization Schedules

2. Routine Schedules

2.1 Schedule A: Basic Immunization for Children Starting Series at 2 Months of Age

- Rotavirus has been removed from 6 months age indication as Rotarix® is now the currently supplied Rotavirus vaccine in BC.
- Varicella has been removed from grade 6 indication, as 2nd dose varicella (provided as MMRV) has been routinely provided at 4-6 years of age since 2013 and the majority of children would have received it prior to grade 6.

2.2 Schedule B: Children 1 to 6 Years of Age (Inclusive) When Starting or Resuming Immunization

- Varicella has been removed from grade 6 indication, as 2nd dose varicella (provided as MMRV) has been routinely provided at 4-6 years of age since 2013 and the majority of children would have received it prior to grade 6.

**Please remove page numbers: 5 & 6 dated October 2020
Please add new page numbers: 5 & 6 dated June 2022**

Part 4 – Biological Products

Human Papillomavirus Vaccines

Human Papillomavirus Vaccine (Nonavalent): Gardasil® 9

- Gender specific language has been revised for clarity and inclusivity, as well as a link to the PHSA glossary of terms related to trans health and services has been included.

Page 1 of 4

- Footnote E has been added to indicate the vaccine is approved for use in males up to 45 years of age, although not yet addressed by NACI.

Please remove page numbers: 1-3 dated June 2019
Please add new page numbers: 1-3 dated June 2022

Monkeypox Vaccine

Smallpox and Monkeypox Vaccine (Live attenuated, non-replicating): INVAMUNE®

- Additional content was added for shipping and storage of vaccine at freezer temperatures of -90°C to -70°C.
- Content added to indicate the vaccine can be stored frozen up until the vaccine's expiry date of 2023-09-30.

Please remove page numbers: 1-2 dated June 10, 2022
Please add new page numbers: 1-2 dated June 24, 2022

Pneumococcal Conjugate Vaccines

Pneumococcal Conjugate Vaccine: Prevnar® 13

A footnote has been added to refer to Part 4 – Biological Products, Completing a Pneumococcal Conjugate Vaccine Series when the basic schedule has been delayed.

Please remove page numbers: 1-3 dated August 2018
Please add new page numbers: 1-3 dated June 2022

Completing a Pneumococcal Conjugate Vaccine Series

- Content in the table has been corrected to indicate high risk infants between 12 and 23 months of age who have previously received 2 doses of PCV prior to 12 months of age require 1 dose for completion of series.
- Footnote A has been revised to indicate that when a high risk condition is diagnosed after completion of a PCV series, no further doses are recommended, except for specific conditions outlined in Part 2 – Immunization of Special Populations (e.g., HSCT recipients).

Please remove page number: 1 dated November 2010
Please add new page number: 1 dated June 2022

Zoster Vaccines

Zoster Vaccine (Recombinant): Shingrix®

- The interval between an episode of shingles and administration of SHINGRIX® in footnote C has been revised to indicate that immunization be deferred until the acute stage of the illness has fully resolved. An interval of 1 year between an episode of shingles and immunization with SHINGRIX® is no longer indicated.
- Special Considerations content has been revised to indicate SHINGRIX® may be considered for immunocompromised adults 18 years of age and older per Health Canada approval.
- Content regarding Guillain-Barré syndrome has been added to the Precautions and Adverse Events sections.

Please remove page numbers: 1-2 dated October 2018

Please add new page numbers: 1-2 dated June 2022

Appendix B: Administration of Biological Products

Instructions on how to open One Point Cut ampules has been updated for clarity in *section 8*.

Please remove entire section: dated May 2022

Please add entire section: dated June 2022

Additional GlaxoSmithKline resources on how to open OPC ampules are available in the circulated educational letter and [video](#). Note that while the operator in the video is using gloves, these are not recommended for routine use in this context.

Supporting Documents

History of Immunization in BC

- The influenza vaccine products used in the 2021-2022 influenza season have been included.
- The rotavirus vaccine table has been updated to indicate ROTARIX® has replaced RotaTeq® as the vaccine routinely given to infants.

Please remove page numbers: 13 & 20 dated December 2020 and August 2020

Please add new page numbers: 13 & 20 dated June 2022

Vaccine Development and Licensing

Biologics and Genetics Therapies Directorate (BGTD) has been updated to Biologic and Radiopharmaceutical Drugs Directorate (BRDD).

Please remove page number: 1-2 dated May 2009
Please add new page numbers: 1-2 dated June 2022

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHS Sc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSA & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division